A history of thrombolytic therapy.
ABSTRACT Thrombolytic therapy has been available for the last 5 decades, but the modern era of thrombolysis began in the early 1990s, with the execution of 3 multicenter trials designed to compare this potentially less invasive therapy to the then standard of care for acute limb ischemia, open surgical revascularization. Even with the development of several bio-engineered lytic agents, the major risk of thrombolytic therapy continues to be bleeding complications. Nevertheless, data exist to suggest that thrombolysis should be considered as an adjunct to open surgery, percutaneous interventions, or, occasionally, as sole therapy for acute vascular occlusion. This review summarizes the developmental milestones in the history of thrombolysis and reviews data supporting its use in acute arterial occlusions.
Article: CONVENTIONAL THROMBOLYTICS NEED TO REFINE AT MOLECULAR LEVEL FOR SAFE AND EFFICIENT MANAGEMENT OF CEREBROVASCULAR DISORDERS- AN OVERVIEW[show abstract] [hide abstract]
ABSTRACT: The cardio and cerebral disorder are the leading cause of vascular traumas which led to many lives threatening consequences and mortality worldwide. In the last few decades numerous artificial molecules have been implemented in clinical application for management and to overcome with devastating vascular traumas. The management of cardiovascular disorders has made remarkable land mark in the health care system with potential thrombolytic agents. Many of artificial fibrinolytic molecules have been used clinically and many more are in refinement phases to tackle the problem. In this study we have composed evolution of thrombolytics from various sources and refinement with technologies. Though these molecules are quite effective for cardiovascular management but often get fail in case of cerebral traumas. The aim of current study is to have an overview on external fibrinolytic molecules their development and clinical applications. Further we have emphasized on the cerebral vascular disorder and their management with currently available thrombolytic molecules. Further we have summarized toxicity offered by conventional thrombolytic in management of cerebral vascular disorder. Finally we have concluded naval approaches which could be further for management of cerebral vascular traumasInternational Journal of Pharmacy and Pharmaceutical Sciences 03/2013; 5(1):448-454.